Adage Capital Partners Gp, L.L.C. Novo Nordisk A S Transaction History

Adage Capital Partners Gp, L.L.C.

$54.6 Billion
Q3 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Novo Nordisk A S stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 794,125 shares of NVO stock, worth $83.6 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

794,125

Previous 759,375 4.58%

Holding current value

$83.6 Million

Previous $108 Million 12.77%

% of portfolio

0.17%

Previous 0.21%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$119.07 - $145.42 $4.14 Million - $5.05 Million	34,750 Added 4.58%	794,125 $94.6 Million
Q2 2024 Aug 14, 2024	SELL	$122.71 - $146.91 $7.17 Million - $8.59 Million	-58,451 Reduced 7.15%	759,375 $108 Million
Q1 2024 May 15, 2024	BUY	$102.11 - $135.92 $350,645 - $466,749	3,434 Added 0.42%	817,826 $105 Million
Q4 2023 Feb 14, 2024	SELL	$87.78 - $105.45 $47.8 Million - $57.4 Million	-544,212 Reduced 40.06%	814,392 $84.2 Million
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $71.1 Million - $156 Million	781,986 Added 135.62%	1,358,604 $124 Million
Q2 2023 Aug 14, 2023	BUY	$155.98 - $172.65 $49.7 Million - $55 Million	318,809 Added 123.66%	576,618 $93.3 Million
Q1 2023 May 15, 2023	SELL	$132.34 - $159.14 $12.8 Million - $15.3 Million	-96,377 Reduced 27.21%	257,809 $41 Million
Q4 2022 Feb 14, 2023	SELL	$102.55 - $135.33 $3.5 Million - $4.61 Million	-34,084 Reduced 8.78%	354,186 $47.9 Million
Q3 2022 Nov 14, 2022	SELL	$95.28 - $116.93 $10.5 Million - $12.9 Million	-110,535 Reduced 22.16%	388,270 $38.7 Million
Q2 2022 Aug 15, 2022	SELL	$103.24 - $121.81 $6.21 Million - $7.33 Million	-60,195 Reduced 10.77%	498,805 $55.6 Million
Q1 2022 May 16, 2022	BUY	$93.1 - $112.54 $3.17 Million - $3.83 Million	34,000 Added 6.48%	559,000 $62.1 Million
Q4 2021 Feb 14, 2022	BUY	$95.88 - $117.08 $50.3 Million - $61.5 Million	525,000 New	525,000 $58.8 Million
Q4 2020 Feb 16, 2021	SELL	$63.89 - $73.8 $6.39 Million - $7.38 Million	-100,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$63.69 - $70.22 $6.37 Million - $7.02 Million	-100,000 Reduced 50.0%	100,000 $6.94 Million
Q2 2020 Aug 14, 2020	SELL	$58.54 - $67.94 $11.7 Million - $13.6 Million	-200,000 Reduced 50.0%	200,000 $13.1 Million
Q1 2020 May 15, 2020	SELL	$49.46 - $64.78 $19.8 Million - $25.9 Million	-400,000 Reduced 50.0%	400,000 $24.1 Million
Q4 2019 Feb 14, 2020	SELL	$49.86 - $58.26 $15 Million - $17.5 Million	-300,000 Reduced 27.27%	800,000 $46.3 Million
Q3 2019 Nov 14, 2019	SELL	$47.54 - $53.43 $23.8 Million - $26.7 Million	-500,000 Reduced 31.25%	1,100,000 $56.9 Million
Q2 2019 Aug 14, 2019	BUY	$46.79 - $52.47 $42.6 Million - $47.7 Million	910,000 Added 131.88%	1,600,000 $81.7 Million
Q1 2019 May 15, 2019	SELL	$46.36 - $52.63 $8.11 Million - $9.21 Million	-175,000 Reduced 20.23%	690,000 $36.1 Million
Q4 2018 Feb 14, 2019	BUY	$41.54 - $47.25 $15.2 Million - $17.2 Million	365,000 Added 73.0%	865,000 $39.9 Million
Q3 2018 Nov 14, 2018	BUY	$46.76 - $51.24 $9.35 Million - $10.2 Million	200,000 Added 66.67%	500,000 $23.6 Million
Q2 2018 Aug 14, 2018	SELL	$44.29 - $50.42 $8.86 Million - $10.1 Million	-200,000 Reduced 40.0%	300,000 $13.8 Million
Q1 2018 May 15, 2018	SELL	$48.49 - $58.14 $9.7 Million - $11.6 Million	-200,000 Reduced 28.57%	500,000 $24.6 Million
Q4 2017 Feb 14, 2018	SELL	$47.53 - $53.73 $4.75 Million - $5.37 Million	-100,000 Reduced 12.5%	700,000 $37.6 Million
Q3 2017 Nov 14, 2017	BUY	$41.15 - $49.22 $32.9 Million - $39.4 Million	800,000	800,000 $38.5 Million

Others Institutions Holding NVO

# of Institutions

1,952

Shares Held

320M

Call Options Held

5.49M

Put Options Held

7.78M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $238B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Novo Nordisk A S Transaction History